Stemline Announces Four SL-401 Presentations at Upcoming ASH Meeting
01. November 2017 09:02 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
Stemline Therapeutics Announces that Pivotal Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Meets Primary Endpoint
31. Oktober 2017 07:00 ET
|
Stemline Therapeutics, Inc.
Detailed results will be presented at the ASH 2017 Annual Meeting (Dec. 9-12)Based on FDA feedback, BLA filing remains on-track Conference call scheduled for today, Tuesday, October 31, 2017 at 8:30AM...
Stemline Therapeutics to Present at Upcoming Investor Conferences
20. September 2017 07:00 ET
|
Stemline Therapeutics
NEW YORK, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
Stemline Therapeutics Presents SL-801 Phase 1 Data at ESMO 2017
11. September 2017 07:00 ET
|
Stemline Therapeutics
NEW YORK, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
Stemline Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
08. September 2017 07:30 ET
|
Stemline Therapeutics
NEW YORK, Sept. 08, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
Stemline Therapeutics to Present SL-801 Phase 1 Data at Upcoming ESMO Congress
30. August 2017 18:10 ET
|
Stemline Therapeutics
NEW YORK, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
Stemline Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference
14. August 2017 07:30 ET
|
Stemline Therapeutics
NEW YORK, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
Stemline Therapeutics Reports Second Quarter 2017 Financial Results
08. August 2017 07:00 ET
|
Stemline Therapeutics
NEW YORK, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
Stemline Therapeutics Presents SL-401 Updated Stage 1 and 2 Data from Ongoing Pivotal Trial in BPDCN and Safety Experience Across Multiple Indications, Today at EHA
23. Juni 2017 09:36 ET
|
Stemline Therapeutics
NEW YORK, June 23, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
Stemline Therapeutics to Present at the Jefferies 2017 Healthcare Conference
06. Juni 2017 07:30 ET
|
Stemline Therapeutics
NEW YORK, June 06, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet...